



Clinical Research Trials

Principal Investigators Include: Stephen Khachikian, MD & Adam Jorgensen, MD

For more information, please call Neili Laughlin for Dr. Jorgensen at 605-719-3204

Rachel Huiskens for Dr. Khachikian at 605-719-3126

Company & Study name	Study Rationale	Study Candidates & Duration	Current Enrollment
Glaucoma Glaukos GLK-101-01 PI: Jorgensen SUBI: Scarborough	Phase 3b, Multicenter, randomized, double-masked trial to evaluate the safety and efficacy of iDOSE® TR (travaprost intraocular implant) in conjunction with the placement of iStent infinite in subjects with open-angle glaucoma or ocular hypertension	Patient with Glaucoma or OHT (Ocular Hypertension) Approximately 12 Months 11 visits total	TBD- please send referral if patient meets criteria
Persistent Corneal Epithelial Defect Glaukos GLK-601-01 PI: Khachikian SUBI: Scarborough	. A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1)	Patients with Persistent Corneal Epithelial Defects (PCED) Approximately 28-60 days	TBD- please send referral if patient meets criteria
	Contact Neili Laughlin for Dr. Jorgensen at 605-719-3204 Rachel Huiskens for Dr. Khachikian at 605-719-3126		